It is possible to substantially enhance these antibodies’ therapeutic potential via humanization, effectively reducing ...

Here we discuss why this is the case and how a cultural shift in the biomedical research community could bring the new technologies for creating antibodies and other tailor-designed binding ...

OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San ...

Transcenta Holding Limited, announced late-breaking presentation of preclinical study results of novel humanized LIV-1 ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate allergen in patients, ...

TuHURA Biosciences (HURA) and Kineta (KANT) announced that they have entered into a definitive merger agreement in which TuHURA would acquire ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Reproducibility is most evident in the immune response, where antibody titers are less variable than via injection. The immune response data are even more compelling given that a lower dose was ...

This organization has no public members. You must be a member to see who’s a part of this organization.